Diligence memo · auto-generated · as of July 2, 2026

Quantum Immunologics, Inc.

Quantum Immunologics, Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Quantum Immunologics, Inc. operates in Pharmaceuticals, based in Tampa.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Quantum Immunologics, Inc. has raised $8.0M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $3.7M on 2009-06-01.

Most recent recorded round closed around 2010-03-29.

Valuation (modeled)modeled

Provath models Quantum Immunologics, Inc. at approximately $62M (range $1.2M–$487M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.04× the median modeled value of Seed Pharmaceuticals companies in 2010–2012 (58 peers) — value vs value, same stage and era. Within the normal band (104% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 3 months.

Last raise 16.3 yr ago; this sector typically re-raises about every 13 months.

Silent for over 3× the sector's normal cadence.

The last round was 1.4× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 50% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 47% of those peers.

Closest niche peers: First China Pharmaceutical Group, Inc., MediQuest Holdings LLC, Ampla Pharmaceuticals Inc, Biomimetix Pharmaceutical, Inc., Prexa Pharmaceuticals Inc.

Peoplefiled

18 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.